← Leaderboards
Tao Zou
Dana-Farber Cancer Inst
$1,044,145
Attributed
$1,044,145
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $208.8K · FY2021–25$250K$187.5K$125K$62.5K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,044,145 · 1
By mechanism
K08$1,044,145 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- David A Barbie$12,794,638
- Pavan Bachireddy$1,087,640
- Alexander H. Stegh$12,620,634
- Toni Choueiri$2,782,193
- Donald W. Kufe$50,160,456
Others in their field
Other Emerging Leaders on “Crispr/Cas Technology”
- William H. Peranteau · Children'S Hosp Of Philadelphia$16,284,236
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,090,386
- Jacqueline K White · Jackson Laboratory$11,881,166
- Jesse M Engreitz · Stanford University$8,776,071
- Peng Jiang · Rutgers, The State Univ Of N.J.$6,578,144
- Yin Shen · University Of California, San Francisco$6,515,212
Research focus
Crispr/Cas TechnologyComputational BiologyCohortCommunitiesAnti-Pd-1/Pd-L1Anti-Tumor Immune ResponseAdvisory CommitteesClinical PracticeBasic ScienceBiological Adaptation To StressBiologyBiopsyCancer BiologyCancer CellCancer Cell LineCancer EtiologyCancer ImmunotherapyCancer ModelCareer DevelopmentCell DeathCellsCell SurvivalCheckpoint InhibitionCyclic Amp-Dependent Protein Kinases
Grant awards (5)
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer$208,829
K08 · FY2025 · CA · contact PI
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer$208,829
K08 · FY2024 · CA · contact PI
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer$208,829
K08 · FY2023 · CA · contact PI
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer$208,829
K08 · FY2022 · CA · contact PI
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer$208,829
K08 · FY2021 · CA · contact PI